Generics in Medicaid Increased in Price and Shifted To Larger Manufacturers Amid 2022-2023 Amphetamine Shortage
Clicks: 2
ID: 315374
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #80 of 98 articles by views in Health Affairs Scholar
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction In late 2022, several manufacturers of immediate-release (IR) amphetamine-based stimulant drugs reported shortages to the FDA. Regulatory requirements for amphetamine and other controlled substances, such as manufacturer-specific quotas set on raw materials, may exacerbate shortage effects on price and quantity. Methods Using 2018-2024 Medicaid State Drug Utilization Data, we studied the impact of the 2022-2023 amphetamine shortage on spending, spending per prescription (i.e., prices), and dispensing of amphetamine products. Results Despite a significant decline in prescriptions dispensed per enrollee following the shortage announcement, gross spending per enrollee increased by 7 percent between 2022-Q2 and 2023-Q1. Prices for generic IR products increased by 6 percent between 2022-Q2 and 2023-Q1 and accounted for more than half of spending growth. Changes in prescription volume varied significantly by manufacturer, with relatively stable trends through the shortage for larger generic manufacturers and sharp declines for smaller manufacturers. Conclusion Despite substantial government oversight in controlled substance markets, prices increased for generics during the shortage. Differences in dispensing across manufacturers implied that, in Medicaid, larger firms adapted more effectively to supply disruptions.
| Reference Key |
openalex_W7162853684
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Anthony Yu, Rosanna Smart, Andrew Mulcahy |
| Journal | Health Affairs Scholar |
| Year | 2026 |
| DOI |
10.1093/haschl/qxag136
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.